SI1885187T1 - Postopki za zdravljenje raka, rezistentnega na zdravila - Google Patents
Postopki za zdravljenje raka, rezistentnega na zdravilaInfo
- Publication number
- SI1885187T1 SI1885187T1 SI200631674T SI200631674T SI1885187T1 SI 1885187 T1 SI1885187 T1 SI 1885187T1 SI 200631674 T SI200631674 T SI 200631674T SI 200631674 T SI200631674 T SI 200631674T SI 1885187 T1 SI1885187 T1 SI 1885187T1
- Authority
- SI
- Slovenia
- Prior art keywords
- methods
- drug resistant
- resistant cancer
- treating drug
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68072205P | 2005-05-13 | 2005-05-13 | |
EP06752445.4A EP1885187B1 (en) | 2005-05-13 | 2006-05-10 | Methods for treating drug resistant cancer |
PCT/US2006/017922 WO2006124413A2 (en) | 2005-05-13 | 2006-05-10 | Methods for treating drug resistant cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1885187T1 true SI1885187T1 (sl) | 2013-12-31 |
Family
ID=37431829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631674T SI1885187T1 (sl) | 2005-05-13 | 2006-05-10 | Postopki za zdravljenje raka, rezistentnega na zdravila |
Country Status (23)
Country | Link |
---|---|
US (1) | US8299081B2 (sl) |
EP (1) | EP1885187B1 (sl) |
JP (2) | JP5344910B2 (sl) |
KR (1) | KR101319122B1 (sl) |
CN (1) | CN101222850B (sl) |
AU (1) | AU2006247803B2 (sl) |
BR (1) | BRPI0610360A2 (sl) |
CA (1) | CA2608171C (sl) |
DK (1) | DK1885187T3 (sl) |
ES (1) | ES2440799T3 (sl) |
HK (1) | HK1110477A1 (sl) |
IL (1) | IL187327A (sl) |
MA (1) | MA29543B1 (sl) |
MX (1) | MX2007014206A (sl) |
NO (1) | NO20076425L (sl) |
NZ (1) | NZ564144A (sl) |
PL (1) | PL1885187T3 (sl) |
PT (1) | PT1885187E (sl) |
RU (1) | RU2426539C2 (sl) |
SI (1) | SI1885187T1 (sl) |
TN (1) | TNSN07419A1 (sl) |
WO (1) | WO2006124413A2 (sl) |
ZA (1) | ZA200709620B (sl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101423513B (zh) * | 2007-10-29 | 2013-03-27 | 中国医学科学院药物研究所 | 胺基嘧啶衍生物、及其制法和药物组合物与用途 |
PL2149372T3 (pl) * | 2008-07-31 | 2015-03-31 | Univ Ulm | Zastosowanie opioidów z grupy metadonu w leczeniu opornych pacjentów onkologicznych |
US9095592B2 (en) * | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US9519613B2 (en) * | 2009-02-02 | 2016-12-13 | Asurion, Llc | Method for integrating applications in an electronic address book |
US8492374B2 (en) | 2009-04-29 | 2013-07-23 | Industrial Technology Research Institute | Azaazulene compounds |
CA2795089A1 (en) * | 2010-04-16 | 2011-10-20 | Novartis Ag | Combination of organic compounds |
CN103547315A (zh) * | 2011-05-19 | 2014-01-29 | 诺华股份有限公司 | 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮 |
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
CN104093402A (zh) * | 2012-01-31 | 2014-10-08 | 诺华股份有限公司 | Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 |
IN2014DN10801A (sl) | 2012-07-11 | 2015-09-04 | Novartis Ag | |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
RU2547999C1 (ru) * | 2013-10-28 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки |
WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
WO2018057618A1 (en) * | 2016-09-20 | 2018-03-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US580883A (en) * | 1897-04-20 | Logging-sled | ||
US3663606A (en) | 1966-06-21 | 1972-05-16 | Mitsui Toatsu Chemicals | Organic imino-compounds |
DE2363459A1 (de) | 1973-12-20 | 1975-06-26 | Basf Ag | Neue fluoreszierende chinolinverbindungen |
DE3248043A1 (de) | 1982-12-24 | 1984-06-28 | Bayer Ag, 5090 Leverkusen | Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten |
US4659657A (en) | 1982-12-24 | 1987-04-21 | Bayer Aktiengesellschaft | Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases |
DE3634066A1 (de) | 1986-10-07 | 1988-04-21 | Boehringer Mannheim Gmbh | Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
US5073492A (en) | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
JPH07121937B2 (ja) | 1987-03-18 | 1995-12-25 | 大塚製薬株式会社 | カルボスチリル誘導体 |
JPH0699497B2 (ja) | 1987-04-16 | 1994-12-07 | 富士写真フイルム株式会社 | 光重合性組成物 |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JPH02229165A (ja) | 1989-03-02 | 1990-09-11 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
GB9107742D0 (en) | 1991-04-11 | 1991-05-29 | Rhone Poulenc Agriculture | New compositions of matter |
GB9108369D0 (en) | 1991-04-18 | 1991-06-05 | Rhone Poulenc Agriculture | Compositions of matter |
GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
DK0584222T3 (da) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
US5856115A (en) | 1991-05-24 | 1999-01-05 | Fred Hutchinson Cancer Research Center | Assay for identification therapeutic agents |
ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
JP3142378B2 (ja) | 1992-06-22 | 2001-03-07 | ティーディーケイ株式会社 | 有機el素子 |
WO1994005333A1 (en) | 1992-09-02 | 1994-03-17 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
JPH0743896A (ja) | 1993-07-28 | 1995-02-14 | Toyobo Co Ltd | 光重合性組成物 |
US5498608A (en) | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
AU5881394A (en) | 1994-01-08 | 1995-08-01 | Rhone-Poulenc Agriculture Limited | Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides |
JPH0829973A (ja) | 1994-07-11 | 1996-02-02 | Toyobo Co Ltd | 光重合性組成物 |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
JP3441246B2 (ja) | 1995-06-07 | 2003-08-25 | 富士写真フイルム株式会社 | 光重合性組成物 |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JP2000501736A (ja) | 1995-12-12 | 2000-02-15 | メルク エンド カンパニー インコーポレーテッド | ロサルタンの新用途 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6010711A (en) | 1996-01-26 | 2000-01-04 | University Of Rochester | Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors |
DE19610723A1 (de) | 1996-03-19 | 1997-09-25 | Bayer Ag | Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen |
US5942385A (en) | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
US6111110A (en) | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
AU3850299A (en) | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
US6174912B1 (en) | 1998-08-21 | 2001-01-16 | Dupont Pharmaceuticals Company | Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists |
DE19841985A1 (de) | 1998-09-03 | 2000-03-09 | Schering Ag | Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate |
US20030087854A1 (en) | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
JP4707240B2 (ja) | 1999-05-05 | 2011-06-22 | アベンティス・フアーマ・リミテッド | 細胞接着調節剤としての尿素 |
KR100298572B1 (ko) | 1999-08-19 | 2001-09-22 | 박찬구 | 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법 |
TR200201051T2 (tr) | 1999-10-19 | 2002-09-23 | Merck & Co., Inc. | Tirosin kinaz inhibitörleri. |
WO2001028993A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
IL151649A0 (en) | 2000-03-07 | 2003-04-10 | Rush Presbyterian St Luke | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
EP1314425A4 (en) | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
EP1351946A2 (en) | 2000-09-01 | 2003-10-15 | Icos Corporation | Materials and methods to potentiate cancer treatment |
ES2334641T3 (es) * | 2000-09-01 | 2010-03-15 | Novartis Vaccines And Diagnostics, Inc. | Derivados aza heterociclicos y su uso terapeutico. |
ES2302106T3 (es) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US20030159702A1 (en) | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
AU2003288899B2 (en) * | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
EP1565187A4 (en) | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | CANCER TREATMENT METHODS AND RELATED METHODS |
US6774327B1 (en) | 2003-09-24 | 2004-08-10 | Agilent Technologies, Inc. | Hermetic seals for electronic components |
WO2005037306A1 (en) | 2003-10-17 | 2005-04-28 | Novo Nordisk A/S | Combination therapy |
JP4724665B2 (ja) | 2003-11-07 | 2011-07-13 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | キノリノン化合物を合成する方法 |
CA2556872C (en) * | 2004-02-20 | 2015-05-12 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
ES2374570T3 (es) * | 2005-01-27 | 2012-02-17 | Novartis Vaccines And Diagnostics, Inc. | Tratamiento de tumores metastalizados. |
BRPI0613200A2 (pt) * | 2005-05-18 | 2012-01-03 | M & G Polimeri Italia Spa | composiÇço de poliÉster |
EP2368566A1 (en) | 2006-07-13 | 2011-09-28 | ZymoGenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
AU2007277144B2 (en) | 2006-07-28 | 2012-01-19 | Novartis Ag | Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma |
-
2006
- 2006-05-10 MX MX2007014206A patent/MX2007014206A/es active IP Right Grant
- 2006-05-10 BR BRPI0610360-0A patent/BRPI0610360A2/pt not_active IP Right Cessation
- 2006-05-10 SI SI200631674T patent/SI1885187T1/sl unknown
- 2006-05-10 PL PL06752445T patent/PL1885187T3/pl unknown
- 2006-05-10 DK DK06752445.4T patent/DK1885187T3/da active
- 2006-05-10 KR KR1020077029071A patent/KR101319122B1/ko not_active IP Right Cessation
- 2006-05-10 US US11/913,828 patent/US8299081B2/en not_active Expired - Fee Related
- 2006-05-10 EP EP06752445.4A patent/EP1885187B1/en not_active Not-in-force
- 2006-05-10 JP JP2008511274A patent/JP5344910B2/ja not_active Expired - Fee Related
- 2006-05-10 AU AU2006247803A patent/AU2006247803B2/en not_active Ceased
- 2006-05-10 NZ NZ564144A patent/NZ564144A/en not_active IP Right Cessation
- 2006-05-10 CN CN2006800256454A patent/CN101222850B/zh not_active Expired - Fee Related
- 2006-05-10 ES ES06752445.4T patent/ES2440799T3/es active Active
- 2006-05-10 PT PT67524454T patent/PT1885187E/pt unknown
- 2006-05-10 WO PCT/US2006/017922 patent/WO2006124413A2/en active Application Filing
- 2006-05-10 RU RU2007145932/15A patent/RU2426539C2/ru not_active IP Right Cessation
- 2006-05-10 CA CA2608171A patent/CA2608171C/en not_active Expired - Fee Related
-
2007
- 2007-11-08 ZA ZA200709620A patent/ZA200709620B/xx unknown
- 2007-11-12 TN TNP2007000419A patent/TNSN07419A1/en unknown
- 2007-11-12 IL IL187327A patent/IL187327A/en not_active IP Right Cessation
- 2007-12-10 MA MA30468A patent/MA29543B1/fr unknown
- 2007-12-13 NO NO20076425A patent/NO20076425L/no not_active Application Discontinuation
-
2008
- 2008-05-06 HK HK08105019.8A patent/HK1110477A1/xx not_active IP Right Cessation
-
2013
- 2013-05-08 JP JP2013098616A patent/JP2013173787A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL187327A0 (en) | Methods for treating drug resistant cancer | |
ZA200805877B (en) | Pyridiazinone derivatives for tumour treatment | |
IL178920A0 (en) | Treatment for pancreatic cancer | |
EP1909854A4 (en) | METHOD FOR TREATING CANCER | |
EP1755394A4 (en) | METHOD OF TREATING CANCER | |
EP1830847A4 (en) | CANCER TREATMENT | |
ZA200705059B (en) | Cancer treatment method | |
GB0609386D0 (en) | Treating drug resistant cancers | |
IL179323A0 (en) | Cancer treatment method | |
HK1110224A1 (en) | Therapeutic agent for cancer | |
IL179359A0 (en) | Cancer treatment method | |
GB0517387D0 (en) | Combinations for the treatment of cancer | |
EP2088862A4 (en) | METHOD OF TREATING CANCER | |
GB0428187D0 (en) | Cancer treatment | |
EP2068911A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
GB0413346D0 (en) | Treating cancer | |
IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
IL226362A0 (en) | compounds, and methods for treating cancer | |
EP1802617A4 (en) | CANCER TREATMENT METHOD | |
HK1225304A1 (zh) | 治療骨癌 | |
ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
ZA200807062B (en) | Specific therapy using integrin ligands for treating cancer | |
GB0507685D0 (en) | Cancer treatment | |
GB0404675D0 (en) | Cancer treatment | |
GB0710871D0 (en) | Cancer treatment |